Phase I Trial and Pharmacokinetic Study of Berubicin (RTA 744) in Patients with Recurrent or Refractory High-Grade Gliomas

Neuro-Oncology Advances · Published 2026-07-31 · DOI 10.1093/noajnl/vdag150

Free full text

Authors (10)

Charles A Conrad, Sigmund H Hsu, Neil Thapar, Elizabeth A Maher, Timothy F Cloughesy, Howard Colman, Mark R Gilbert, Vinay K Puduvalli, Timothy Madden, Waldemar Priebe

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Conrad, C., Hsu, S., Thapar, N., et al. (2026). Phase I Trial and Pharmacokinetic Study of Berubicin (RTA 744) in Patients with Recurrent or Refractory High-Grade Gliomas. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdag150

Related articles

• Cognitive dysfunction associated with cellular immunotherapy for cancer · Neuro-Oncology Advances · 2026 · Same journal
• The molecular profile of gliomas in adolescents and young adults · Neuro-Oncology Advances · 2026 · Same journal
• Immunogenomic Profiling Reveals Targets for Gene Therapy in Pediatric Brain Tumors · Neuro-Oncology Advances · 2026 · Same journal
• Emotional distress impairs immune checkpoint blockade efficacy in recurrent high-grade glioma: Insights from tumor in situ fluid analysis · Neuro-Oncology Advances · 2026 · Same journal
• Mutational signature stratification of recurrent gliomas reveals distinct patterns of genomic traits · Neuro-Oncology Advances · 2026 · Same journal
• Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives · Neuro-Oncology Advances · 2026 · Same journal
• ASL-based Exchange Time Mapping for Differentiation of High-Grade Glioma and Brain Metastases · Neuro-Oncology Advances · 2026 · Same journal
• Disturbance of functional connectivity in patients with low grade glioma is associated with worse progression–free survival · Neuro-Oncology Advances · 2026 · Same journal
• The Cell Surface Proteome of Malignant Peripheral Nerve Sheath Tumors Reveals Therapeutic Targets · Neuro-Oncology Advances · 2026 · Same journal
• Boron neutron capture therapy plus bevacizumab versus bevacizumab alone in recurrent glioblastoma: A propensity score–matched analysis · Neuro-Oncology Advances · 2026 · Same journal